Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, et al. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial. Ann Intern Med. 2017;167(5):311–8. https://doi.org/10.7326/M17-0118.

Article  PubMed  PubMed Central  Google Scholar 

Wilson E, Covert E, Hoffmann J, Comstock E, Emmanuel B, Tang L, et al. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). J Hepatol. 2019;71(3):498–504. https://doi.org/10.1016/j.jhep.2019.05.021. This study demonstrated effective re-treatment of patients co-infected with HIV and HCV, which had previously been a population that was difficult to treat.

Wyles DL, Luetkemeyer AF. Understanding hepatitis C virus drug resistance: clinical implications for current and future regimens. Top Antivir Med. 2017;25(3):103–9.

PubMed  PubMed Central  Google Scholar 

The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2018.

Wilson EM, Rosenthal ES, Kattakuzhy S, Tang L, Kottilil S. Clinical laboratory testing in the era of directly acting antiviral therapies for hepatitis C. Clin Microbiol Rev. 2017;30(1):23–42. https://doi.org/10.1128/CMR.00037-16.

CAS  Article  PubMed  Google Scholar 

Kattakuzhy S, Levy R, Kottilil S. Sofosbuvir for treatment of chronic hepatitis C. Hepatol Int. 2015;9(2):161–73. https://doi.org/10.1007/s12072-014-9606-9.

Article  PubMed  Google Scholar 

Mathur P, Kottilil S, Wilson E. Use of ribavirin for hepatitis C treatment in the modern direct-acting antiviral era. J Clin Transl Hepatol. 2018;6(4):431–7. https://doi.org/10.14218/JCTH.2018.00007.

Article  PubMed  PubMed Central  Google Scholar 

Soria ME, Gregori J, Chen Q, Garcia-Cehic D, Llorens M, de Avila AI, et al. Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus. BMC Infect Dis. 2018;18(1):446. https://doi.org/10.1186/s12879-018-3356-6.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Soriano V, Fernandez-Montero JV, de Mendoza C, Benitez-Gutierrez L, Pena JM, Arias A, et al. Treatment of hepatitis C with new fixed dose combinations. Expert Opin Pharmacother. 2017;18(12):1235–42. https://doi.org/10.1080/14656566.2017.1346609.

CAS  Article  PubMed  Google Scholar 

Ruzicka DJ, Tetsuka J, Fujimoto G, Kanto T. Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016. BMC Infect Dis. 2018;18(1):237. https://doi.org/10.1186/s12879-018-3148-z.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Ottman AA, Townsend ML, Hashem MG, DiMondi VP, Britt RB. Incidence of drug interactions identified by clinical pharmacists in veterans initiating treatment for chronic hepatitis C infection. Ann Pharmacother. 2018;52(8):763–8. https://doi.org/10.1177/1060028018766507.

CAS  Article  PubMed  Google Scholar 

Slevin AR, Hart MJ, Van Horn C, Rahman S, Samji NS, Szabo A, et al. Hepatitis C virus direct-acting antiviral nonadherence: relationship to sustained virologic response and identification of at-risk patients. J Am Pharm Assoc (2003). 2019;59(1):51–6. https://doi.org/10.1016/j.japh.2018.10.020.

Article  Google Scholar 

Norton BL, Akiyama MJ, Agyemang L, Heo M, Pericot-Valverde I, Litwin AH. Low adherence achieves high HCV cure rates among people who inject drugs treated with direct-acting antiviral agents. Open Forum Infect Dis. 2020;7(10):ofaa377. https://doi.org/10.1093/ofid/ofaa377.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Perez AB, Chueca N, Garcia F. Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long? Germs. 2017;7(1):40–4. https://doi.org/10.18683/germs.2017.1107.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Harrington PR, Komatsu TE, Deming DJ, Donaldson EF, O'Rear JJ, Naeger LK. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: regulatory analyses and perspectives. Hepatology. 2017. https://doi.org/10.1002/hep.29693. This study showed that that baseline HCV RAVs can reduce the efficacy of certain DAA-based regimens in selected patient groups.

Jimenez-Sousa MA, Gutierrez-Rivas M, Alvaro-Meca A, Garcia-Alvarez M, Harrigan PR, Fedele CG, et al. NS3 resistance-associated variants (RAVs) in patients infected with HCV genotype 1a in Spain. PLoS ONE. 2016;11(9): e0163197. https://doi.org/10.1371/journal.pone.0163197.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Ahmed A, Felmlee DJ. Mechanisms of hepatitis C viral resistance to direct acting antivirals. Viruses. 2015;7(12):6716–29. https://doi.org/10.3390/v7122968.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62(5):1623–32. https://doi.org/10.1002/hep.27934. This is a comprehensive systematic review that discusses the viral proteins targeted by DAAs and summarizes clinically relevant resistance data.

Zuckerman A, Chastain CA, Naggie S. Retreatment options following HCV direct acting antiviral failure. Curr Treat Options Infect Dis. 2017;9(4):389–402. https://doi.org/10.1007/s40506-017-0136-6.

Article  PubMed  PubMed Central  Google Scholar 

Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, et al. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017;37(4):514–28. https://doi.org/10.1111/liv.13327.

CAS  Article  PubMed  Google Scholar 

Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66(5):910–8. https://doi.org/10.1016/j.jhep.2017.01.007.

CAS  Article  PubMed  Google Scholar 

Zepatier [package insert]. Merck & Co., Inc. Whitehouse Station, NJ. 2017.

Vermehren J SS, Dietz J, et al. Retreatment of patients who failed DAA-combination therapies: realworld experience from a large hepatitis C resistance database [Abstract PS103]. 51st Annual Meeting of the European Association for the Study of the Liver (EASL). Barcelona, Spain2016. This real-world study used resistance assays of patients who failed previous treatment with DAAs to guide re-treatment therapy selection and had SVR rates >90%.

Cento V BS, Bonora S, et al. Optimal efficacy of HCV resistance-based retreatments after PI failure [Abstract 565]. The Annual Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, Washington, USA 2017.

Pérez AB CN, García-Deltoro, M et al. Retreatment options after failing a first line of DAAs against hepatitis C virus [Abstract 566]. The Annual Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, Washington, USA 2017.

Lawitz E FS, Yang JC, et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks [Abstract 0005]. 50th Annual Meeting of the European Association for the Study of the Liver (EASL) 2015.

Wilson EM, Kattakuzhy S, Sidharthan S, Sims Z, Tang L, McLaughlin M, et al. Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens. Clin Infect Dis. 2016;62(3):280–8. https://doi.org/10.1093/cid/civ874.

CAS  Article  PubMed  Google Scholar